(Logo via Johnson & Johnson)

Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis

Originally Published on JNJ.com  

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubagio®* (teriflunomide) in adults with relapsing multiple sclerosis. The study met its primary and most secondary endpoints.

Ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, a class of drugs that is believed to functionally inhibit S1P activity and reduce the number of circulating lymphocytes by trapping them in the lymph nodes. Therefore, there are less inflammatory cells available to cross into the central nervous system (CNS) where they could damage myelin. Myelin is a protective sheath that insulates nerve cells and is damaged in patients with multiple sclerosis.[i]

The primary endpoint of OPTIMUM was annualized relapse rate (ARR) up to the end of the study. A key secondary endpoint was change from baseline to week 108 in fatigue-related symptoms. Fatigue is considered a significant unmet need from patients’ perspective. Additionally, the study evaluated other secondary endpoints: cumulative number of combined unique active lesions (CUALs) using magnetic resonance imaging (MRI), time to first 12-week confirmed disability accumulation (CDA) and time to first 24-week CDA from baseline to end of the study.

The safety profile observed for ponesimod in the OPTIMUM study was consistent with previous studies of ponesimod, and the known safety profile for other S1P receptor modulators.

OPTIMUM was a head-to-head, prospective, multicenter, randomized, double-blind, active controlled, parallel-group, Phase 3 superiority study to compare efficacy, safety and tolerability of ponesimod 20 mg versus teriflunomide 14 mg in adults with relapsing multiple sclerosis. The study included 1,133 participants with the treatment duration of 108 weeks.

Data from the OPTIMUM study have been accepted for presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019.

Data from the OPTIMUM study will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of ponesimod as a treatment for relapsing forms of multiple sclerosis, which are anticipated for later this year.

 

Latest News

A Look at the Current State of Women’s Diversity in Corporate America

DEI professionals and women’s rights advocates alike have been pressing for greater equity, representation and inclusion for female workers in America’s boardrooms for decades. While strides have been made in the 170 years since the dawn of women’s suffrage and the 1848 Seneca Falls Women’s Rights Convention, which marked the…

Creating Pay Equity and Equal Treatment for Employees

Even though the disparity in pay has been a high-profile issue for decades, it remains a concern for businesses across every industry. HR professionals and business leaders continue to search for ways to create pay equity between genders and those of different ethnic and racial backgrounds. Some may face mandates…

5 Biggest News Stories of the Week: August 11

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. Eli Lilly Plans…

The Importance of Business-Community Partnerships

Businesses increasingly play a key role in building stronger communities. It’s something that people in the past few years have come to expect. It’s created not only a way to improve local communities, but also boost an organization’s employee morale, loyalty and brand reputation. One of the main ways businesses…

CDO Series: Humana’s Carolyn Tandy

Following the murder of George Floyd, the role of Chief Diversity Officers has become more important as companies started to be more intentional with their diversity, equity and inclusion efforts, which has made the last few years tumultuous for many CDOs. In the first interview of a series of articles…